Modern approaches to pharmacotherapy of chronic glomerulonephritis

Abstract

Chronic glomerulonephritis is a dangerous disease that leads to chronic kidney disease. In the terminal stage patients need dialysis, which is difficult to access for a large part of the Russian population. It is the very high-quality conservative treatment that allows to delay the onset of the terminal stage of this disease. The main role in pathogenesis is played by the immune complexes that appear and are deposited in the renal glomeruli, which causes immune damage. According to the clinical course and taking into account the prevailing symptoms chronic glomerulonephritis is divided into latent, nephrotic, hematuric, hypertonic and mixed types, prescribed therapy depends on the morphology and clinical course. Clinically and morphologically chronic glomerulonephritis lasts over 1 year. Drug treatment for chronic glomerulonephritis supposes therapy that involves suppression of immune inflammation and intravascular changes. Rituximab is a chimeric glycosylated human or murine immunoglobulin that has specific affinity for the B-lymphocyte transmembrane protein CD20 causing the lysis of circulating CD20 cells.